Business context and reporting period
VivoSim Labs, Inc. (Nasdaq: VIVS) filed this Form 8-K to report results of its September 30, 2026 annual meeting of stockholders. The filing reports corporate and capital-structure matters, not quarterly or annual operating results.
Financial and operating metrics
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or guidance figures. It states that 16,586,495 common shares were outstanding on the August 13, 2026 record date; 6,180,635 shares, or 37.26%, were represented at the meeting, constituting a quorum.
Material changes and meeting outcomes
- Equity plan: Stockholders approved an amendment and restatement of the 2022 Equity Incentive Plan, adding 3,165,000 shares to the plan reserve. It became effective immediately upon approval. The filing does not state the resulting total reserve.
- Reverse split authorization: Stockholders approved an amendment allowing the Board, at its discretion on or before September 30, 2027, to effect a 1-for-5 to 1-for-20 reverse split, including any ratio in between. The authorized share count would not be reduced, and no further stockholder approval is required.
- Warrants and private placement: Stockholders approved issuance of 4,705,883 common shares upon exercise of warrants issued in the July 2026 private placement, and a reduction in the exercise price of certain May 13, 2024 warrants from $9.60 to $0.85 per share.
- Other votes: Keith Murphy and Adam Stern were elected as Class III directors through the 2029 annual meeting. Stockholders ratified Rosenberg Rich Baker Berman P.A. as auditor for the fiscal year ending March 31, 2027, and approved the named executive officer compensation on a non-binding advisory basis.
Vote results and investor considerations
| Proposal | Approval reported |
|---|---|
| Auditor ratification | 92.51% of votes cast |
| Executive compensation advisory vote | 76.33% of votes cast |
| Reverse split authorization | 74.12% of votes cast |
| Equity plan increase | 72.52% of votes cast |
| Warrant-related approvals | 77.87% of votes cast |
The filing provides no management outlook, financial guidance, or discussion of operating risks or contingencies. The key potential capital-structure implications are the additional equity-plan shares, possible warrant exercises, the reduced exercise price on certain warrants, and the Board’s ability to implement a reverse split without another stockholder vote.
Important facts to verify
- Review the full amended and restated equity plan, including the total shares reserved, in Exhibit 10.1 and the referenced proxy statement.
- Confirm the status and terms of the July 2026 private placement warrants, including potential exercise timing and resulting dilution.
- Review the May 2024 warrant documents to confirm the effect and conditions of the exercise-price reduction to $0.85.
- Monitor whether the Board exercises the reverse split authority, and the selected ratio and timing.